TaiMed Biologics (TPEX: 4147) announced today that in response to market concerns regarding the potential impact of former U.S. President Donald Trump’s tariff policies and related legal rulings, the Company has completed confirmation with its manufacturing partner, Samsung Biologics (SBL), for Trogarzo® (ibalizumab-uiyk). At present, pharmaceutical products exported from South Korea to the United States continue to enjoy zero-tariff treatment and are not subject to the newly announced Section 122 tariff measures.

Recently, the U.S. Supreme Court issued a ruling regarding tariffs imposed under the International Emergency Economic Powers Act (IEEPA), determining that the statute does not authorize the President to unilaterally impose tariffs. The related measures have therefore been declared unlawful. In addition, prior to the formal announcement and implementation of measures under Section 232 of the U.S. Trade Expansion Act, pharmaceutical products remain subject to existing exemption principles and are not included within the scope of the newly announced Section 122 tariffs. As such, pharmaceutical exports from South Korea to the United States currently remain subject to zero tariffs.

Trogarzo® is manufactured in South Korea by Samsung Biologics and supplied to the U.S. market. Based on the latest confirmation, product exportation, customs clearance, and market supply operations remain normal. No additional tariff costs have been incurred, and there has been no impact on the Company’s operations or gross margin structure.

TaiMed Biologics will continue to closely monitor U.S. trade policies and regulatory developments, maintain real-time communication with its manufacturing and commercial partners, ensure stable product supply and patient access, and prudently assess any potential impact of policy changes on the Company’s operations.